Auriol S, Mahieu L, Lequeux L, Quintyn J C, Pagot-Mathis V
Service d'ophtalmologie, CHU Rangueil, Toulouse, France.
J Fr Ophtalmol. 2010 Feb;33(2):84-91. doi: 10.1016/j.jfo.2009.12.005. Epub 2010 Jan 25.
The natural prognosis of eyes with subretinal hemorrhage resulting from age-related macular degeneration is generally poor. A variety of therapeutic approaches have been developed but no consensus was found. Therefore, we evaluated a technique consisting of pars plana vitrectomy and subretinal rt-PA injection followed by evacuation of the liquid blood using sulfur hexafluoride (SF6).
This study was a retrospective clinical case series examining 18 eyes of 16 patients with age-related macular degeneration and thick submacular hemorrhage treated with vitrectomy, subretinal injection of rt-PA (0.5mg), and fluid-gas exchange.
The subretinal hemorrhage was displaced in all 18 cases, revealing a choroidal lesion in 17 eyes. A treatable lesion accountable for the bleeding was identified in ten eyes, which all received a secondary treatment (intravitreal injection or photodynamic therapy). After a mean follow-up of 6 months, the final visual acuity improved in ten eyes. Complications consisted of one case of retinal detachment and one case of hyphema.
This surgical technique seems useful in displacing thick submacular hemorrhage secondary to age-related macular degeneration, allowing postoperative fluorescein angiography testing and, potentially, subsequent treatments. However, further controlled and multicentric studies will be required to assess its efficacy and safety in the management of this difficult clinical problem.
年龄相关性黄斑变性导致的视网膜下出血眼的自然预后通常较差。已经开发了多种治疗方法,但尚未达成共识。因此,我们评估了一种技术,该技术包括玻璃体切除术和平坦部视网膜下注射重组组织型纤溶酶原激活剂(rt-PA),随后使用六氟化硫(SF6)清除液态血液。
本研究是一项回顾性临床病例系列研究,检查了16例年龄相关性黄斑变性和黄斑下厚出血患者的18只眼,这些患者接受了玻璃体切除术、视网膜下注射rt-PA(0.5mg)和气液交换。
18例患者的视网膜下出血均移位,17只眼显示脉络膜病变。在10只眼中发现了导致出血的可治疗病变,这些眼均接受了二次治疗(玻璃体腔内注射或光动力疗法)。平均随访6个月后,10只眼的最终视力有所改善。并发症包括1例视网膜脱离和1例前房积血。
这种手术技术似乎有助于移位年龄相关性黄斑变性继发的黄斑下厚出血,允许术后进行荧光素血管造影检查,并可能进行后续治疗。然而,需要进一步的对照和多中心研究来评估其在处理这一棘手临床问题中的疗效和安全性。